Abstract
Treatment of hypertension with the major available antihypertensive classes results in a significant improvement in cardiovascular morbidity and mortality. However, there is controversy about whether specific classes of drug therapy have deleterious or beneficial effects on glucose and lipid metabolism. Myths and misconceptions have thus arisen. Although “old” classes of antihypertensives, such as diuretics and β-blockers, seem to have deleterious effects on glucose and lipid metabolism, the “newer” agents appear to have either neutral or beneficial profiles. The long-term significance of these metabolic changes is still debated. It is known that insulin resistance plays a major role in the pathogenesis of hypertension and type 2 diabetes mellitus. There is increasing evidence that blocking the renin-angiotensin-aldosterone system by using angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers favorably affects insulin sensitivity and, accordingly, decreases the incidence of new-onset type 2 diabetes mellitus.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References and Recommended Reading
Chobanian AV, Bakris GL, Black HR, et al.: Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003, 42:1206–1252.
Hajjar I, Kotchen TA: Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000. JAMA 2003, 90:199–206.
Sowers JR: Insulin resistance and hypertension. Am J Physiol Heart Circ Physiol 2004, 286:H1597-H1602. The relationship between hypertension and insulin resistance is reviewed in this paper. It illustrates the inhibitory effects of angiotensin II on insulin signaling pathways in the vessels and skeletal muscles.
McFarlane SI, Banerji M, Sowers JR:. Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab 2001, 86:713–718.
Gress TW, Nieto FJ, Shahar E, et al.: Hypertension and antihypertensive therapy as risk factors for type 2 mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000, 342:905–912.
Garcia-Puig J, Ruilope LM, Luque M, et al.: AVANT Study Group Investigators: Glucose metabolism in patients with essential hypertension. Am J Med 2006, 119:318–326.
Hypertension in Diabetes Study (HDS): I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertens 1993, 11:309–317.
Haffner SM, Stern MP, Hazuda HP, et al.: Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 1990, 263:2893–2898.
Bakris GL, Sowers JR: When does new onset diabetes resulting from antihypertensive therapy increase cardiovascular risk. Hypertension 2004, 43:941–942.
Stas SN, El-Atat FA, Sowers JR: Pathogenesis of hypertension in diabetes. Rev Endocr Metab Disord 2004, 5:221–225. In this review article, the mechanisms involved in the development of hypertension and insulin-resistant states, including diabetes, are discussed.
Gill H, Mugo M, Whaley-Connell A, et al.: The key role of insulin resistance in the cardiometabolic syndrome. Am J Med Sci 2005, 330:290 -294.
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998, 317:703–713.
Lindholm LH, Persson M, Alaupovic P, et al.: Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens 2003, 21:1563–1574.
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288:2981–2997.
Verdecchia P, Reboldi G, Angeli F, et al.: Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004, 43:963–969. This long-term follow-up study examined the predictive ability of new-onset diabetics in hypertensives. It shows that the levels of CVD events in these individuals on antihypertensives were comparable with those levels found in previously known diabetics.
Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000, 22:253–259.
Mancia G, Brown M, Castaigne A, et al.: Outcomes with nifedipine GITS or co-amilozide in hypertensive diabetics and nondiabetics in Intervention as a Goal in Hypertension (INSIGHT). Hypertension 2003, 41:431–436.
Bakris GL, Gaxiola E, Messerli FH: Clinical outcomes in the diabetes cohort of the International Verapamil SR-Trandolapril study. Hypertension 2004, 44:637–642.
Hansson L, Lindholm LH, Niskanen L, et al.: Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999, 353:611–616.
Lindholm LH, Ibsen H, Dahlof B, et al.: LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:1004 -1010.
McMurray JJ, Ostergren J, Swedberg K, et al.: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARMAdded trial. Lancet 2003, 362:767–771.
Padwal R, Laupacis A: Antihypertensive therapy and incidence of type 2 diabetes: a systematic review. Diabetes Care 2004, 27:247–255.
Whelton PK, Barzilay J, Cushman WC, et al.: Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2005, 165:1401–1409.
Goldner MG, Zarowitz H, Akgun S: Hyperglycemia and glycosuria due to thiazide derivatives administered in diabetes mellitus. N Engl J Med 1960, 262:403–405.
Carter BL, Basile J: Development of diabetes with thiazide diuretics: the potassium issue. J Clin Hypertens (Greenwich) 2005, 7:638–640.
Mancia G, Grassi G, Zanchetti A: New-onset diabetes and antihypertensive drugs. J Hypertens 2006, 24:3–10.
Wing LM, Reid CM, Ryan P, et al.: for the Second Australian National Blood Pressure Study Group: A comparison of outcomes with angiotensin-converting enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003, 348:583–592.
Sowers JR, Bakris GL: Antihypertensive therapy and the risk of type 2 diabetes mellitus. N Engl J Med 2000, 342:969–970.
Neaton JD, Grimm RH Jr, Prineas RJ, et al.: Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group. JAMA 1993, 270:713–724.
Sica DA: Diuretic-related side effects: development and treatment. J Clin Hypertens (Greenwich) 2004, 6:532–540.
Mantel-Teeuwisse AK, Kloosterman JM, Maitland-van der Zee AH, et al.: Drug-induced lipid changes: a review of the unintended effects of some commonly used drugs on serum lipid levels. Drug Saf 2001, 24:443–456.
Lakshman MR, Reda DJ, Materson BJ, et al.: Diuretics and beta-blockers do not have adverse effects at 1 year on plasma lipid and lipoprotein profiles in men with hypertension. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Arch Intern Med 1999, 159:551–558.
Sarafidis PA, Bakris GL: Are beta blockers passé for the treatment of hypertension? J Clin Hypertens (Greenwich) 2006, 8:239–240.
Bell DS: Beta-adrenergic blocking agents in patients with diabetes—friend and foe. Endocr Pract 1999, 5:51–53.
Jacob S, Henriksen EJ: Metabolic properties of vasodilating beta blockers: management considerations for hypertensive diabetic patients and patients with the metabolic syndrome. J Clin Hypertens (Greenwich) 2004, 6:690–696.
Giugliano D, Acampora R, Marfella R, et al.: Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann Intern Med 1997, 126:955–959.
Bakris GL, Fonseca V, Katholi RE, et al.: Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004, 292:2227–2236.
Julius S, Kjeldsen SE, Weber M, et al.: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004, 363:2022–2031.
Gillespie EL, White CM, Kardas M,: The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes. Diabetes Care 2005, 28:2261–2266.
Scheen AJ: Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 2. Overview of physiological and biochemical mechanisms. Diabetes Metab 2004, 30:498–505.
McFarlane SI, Kumar A, Sowers JR: Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease. Am J Cardiol 2003, 91:30H-37H.
Blendea MC, Jacobs D, Stump CS, et al.: Abrogation of oxidative stress improves insulin sensitivity in the Ren-2 rat model of tissue angiotensin II overexpression. Am J Physiol Endocrinol Metab 2005, 288:E353-E359.
Schupp M, Janke J, Clasen R, et al.: Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004, 109:2054–2057.
Abuissa H, Jones PG, Marso SP, et al.: Angiotensinconverting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 2005, 46:821–826. After conducting a meta-analysis of the major controlled clinical trials on ACEs and ARBs, these authors concluded that the use of these specific antihypertensive agents in pre-diabetics should be considered in the prevention of T2DM.
Kyvelou SM, Vyssoulis GP, Karpanou EA, et al.: Effects of antihypertensive treatment with angiotensin II receptor blockers on lipid Profile: an open multi-drug comparison trial. Hellenic J Cardiol 2006, 47:21–28.
Hanefeld M, Abletshauser C: Effect of the angiotensin II receptor antagonist valsartan on lipid Profile and glucose metabolism in patients with hypertension. J Int Med Res 2001, 29:270–279.
Mukasa K: Antihypertensive drugs and insulin resistance in obesity. Intern Med 2005, 44:395–396.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Stas, S., Appesh, L. & Sowers, J. Metabolic safety of antihypertensive drugs: Myth versus reality. Current Science Inc 8, 403–408 (2006). https://doi.org/10.1007/s11906-006-0086-8
Issue Date:
DOI: https://doi.org/10.1007/s11906-006-0086-8